Everest Medicines launched VELSIPITY in Mainland China after NMPA approval on February 2, 2026. The first prescription was issued at The First Affiliated Hospital of Sun Yat-sen University.
NRx Pharmaceuticals said an FDA Type C meeting indicated a path to an NDA for NRX-100, using clinical trial results and real-world ketamine data from more than 65,000 patients.
New data from LIBERTY studies show subcutaneous infliximab effectively restored and maintained disease control in Crohn's disease and ulcerative colitis patients after drug holiday of 16 weeks or more, with sustained efficacy through Week 102.
